These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9227164)

  • 21. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
    Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
    Masud T; Mulcahy B; Thompson AV; Donnelly S; Keen RW; Doyle DV; Spector TD
    Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
    Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
    Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C; Oriente P; Laan R; Hughes RA; Ittner J; Goemaere S; Di Munno O; Pouillès JM; Horlait S; Cortet B
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.
    Guañabens N; Farrerons J; Perez-Edo L; Monegal A; Renau A; Carbonell J; Roca M; Torra M; Pavesi M
    Bone; 2000 Jul; 27(1):123-8. PubMed ID: 10865219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S; Takada T; Katsuki Y; Kimura N; Kaneko Y; Suwa A; Hirakata M; Kuwana M
    J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
    Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
    Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J; Cranney A; Goldsmith CH; Bensen WG; Bianchi F; Cividino A; Craig GL; Kaminska E; Sebaldt RJ; Papaioannou A
    J Rheumatol; 1994 Oct; 21(10):1922-6. PubMed ID: 7837160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol.
    Fujita T; Orimo H; Inoue T; Kaneda K; Sakurai M; Morita R; Yamamoto K; Sugioka Y; Inoue A; Takaoka K; Yamamoto I; Hoshino Y; Kawaguchi H
    J Bone Miner Metab; 2007; 25(2):130-7. PubMed ID: 17323183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
    Crilly RG; Sebaldt RJ; Hodsman AB; Adachi JD; Brown JP; Goldsmith CH; Hanley DA; Olszynski WO; Ste-Marie LG; Stephenson GF
    Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
    Orme SM; Simpson M; Stewart SP; Oldroyd B; Westmacott CF; Smith MA; Belchetz PE
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):245-50. PubMed ID: 7923830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
    J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years.
    Guañabens N; Parés A; Monegal A; Peris P; Pons F; Alvarez L; de Osaba MJ; Roca M; Torra M; Rodés J
    Gastroenterology; 1997 Jul; 113(1):219-24. PubMed ID: 9207281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
    Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
    Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.